论文部分内容阅读
有研究指出缺血组织和肿瘤的新血管系统均源自于新血管发生,而骨髓源性的循环内皮祖细胞(bone marrow-derived circulating endothelial progenitor cell,BMCEPC)有利于血管的形成,而之前认为此机制仅发生在胚胎的血管之中,内皮祖细胞(endothelial progenitor cell,EPC)的发现改变了这一观念并因此引入了一种关于血管再生的治疗新理念,EPC相关的缺血及肿瘤治疗的临床前研究已应用于人类缺血疾病的试验性治疗。
It has been pointed out that neovascularization of ischemic tissues and tumors originated from neovascularization and that bone marrow-derived circulating endothelial progenitor cells (BMCEPC) favored the formation of blood vessels. Previously, This mechanism occurs only in the blood vessels of the embryo and the discovery of endothelial progenitor cells (EPCs) has changed this concept and has therefore led to the introduction of a new therapeutic concept of angiogenesis, EPC-related ischemia and oncology treatment The preclinical study has been applied to the experimental treatment of human ischemic disease.